🔎 Trials Near Me

Domov › Crohnova bolezen › Ohio

Klinične študije za Crohnova bolezen v Ohio

30 študij za Crohnova bolezen išče udeležence na lokacijah v Ohio.

Mesta v Ohio

Uradno besedilo študije (angleško)

A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)

  • Great Lakes Gastroenterology Research, LLC ( Site 5016), Mentor
Vključevanje udeležencevFaza 3
Starost 16–80 · Vsi spoli · Posodobljeno 2. okt. 2026 · NCT06430801

Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis

  • Gastro Intestinal Research Institute of Northern Ohio /ID# 283860, Westlake
Vključevanje udeležencevFaza 2
Starost 18–75 · Vsi spoli · Posodobljeno 2. okt. 2026 · NCT07697456

Investigating the Effect of the Non-nutritive Sweetener Sucralose in Inflammatory Bowel Disease

  • UH Minoff Health Center, Chagrin Falls
  • University Hospitals Cleveland Medical Center, Cleveland
  • UH Westlake Health Center, Westlake
Vključevanje udeležencevVabljeni zdravi prostovoljci
Starost 18–75 · Vsi spoli · Posodobljeno 1. okt. 2026 · NCT07852273

A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting

  • Gastro Health Research - Cincinnati, Cincinnati
  • DSI Research Northridge LLC, Dayton
  • Gastro Health Research - Liberty Township, Liberty Township
  • in še 3
Vključevanje udeležencevFaza 4
Starost 18–80 · Vsi spoli · Posodobljeno 30. sep. 2026 · NCT06581328

Non-nutritive Sweeteners in Inflammatory Bowel Disease

  • UH Minoff Health Center, Chagrin Falls
  • University Hospitals Cleveland Medical Center, Cleveland
  • UH Westlake Health Center, Westlake
Vključevanje udeležencevVabljeni zdravi prostovoljci
Starost 18–70 · Vsi spoli · Posodobljeno 25. sep. 2026 · NCT07769437

Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease

  • University of Cincinnati /ID# 265589, Cincinnati
  • The Ohio State University /ID# 265577, Columbus
Vključevanje udeležencevFaza 2
Starost 18–75 · Vsi spoli · Posodobljeno 25. sep. 2026 · NCT06548542

A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease

  • Great Lakes Gastroenterology Research, LLC, Mentor
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 25. sep. 2026 · NCT07499232

A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants

  • Cincinnati Children's Hospital Medical Center, Cincinnati
Vključevanje udeležencevFaza 3
Starost 3 in več · Vsi spoli · Posodobljeno 25. sep. 2026 · NCT06663332

A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease

  • Great Lakes Gastroenterology Research, LLC, Mentor
Vključevanje udeležencevFaza 2
Starost 18–75 · Vsi spoli · Posodobljeno 25. sep. 2026 · NCT06233461

Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

  • Gastro Intestinal Research Institute of Northern Ohio, LLC, Westlake
Vključevanje udeležencevFaza 3
Starost 18–70 · Vsi spoli · Posodobljeno 24. sep. 2026 · NCT06937099

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

  • Ohio State University Comprehensive Cancer Center, Columbus
Vključevanje udeležencevFaza 1
Starost 18 in več · Vsi spoli · Posodobljeno 23. sep. 2026 · NCT03816345

An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease

  • Gastroenterology & Hepatology Specialists, Inc.-Site nUmber: 8400139, Canton
  • University Hospitals Cleveland Medical Center-Site Number: 8400073, Cleveland
  • Ohio Gastroenterology Group Inc.-8400006, Columbus
  • in še 5
Vključevanje udeležencevFaza 3
Starost 16–80 · Vsi spoli · Posodobljeno 23. sep. 2026 · NCT07184931

A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease

  • Ohio Gastroenterology Group Inc.-Site Number: 8400006, Columbus
  • Medical Associates Research Group-Site Number: 8400063, Columbus
  • OSU Wexner Medical Center-Site Number: 8400077, Columbus
  • in še 1
Vključevanje udeležencevFaza 3
Starost 16–80 · Vsi spoli · Posodobljeno 23. sep. 2026 · NCT07184944

A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease

  • Cleveland Clinic - Cleveland /ID# 256453, Cleveland
Vključevanje udeležencevFaza 3
Starost 2–17 · Vsi spoli · Posodobljeno 23. sep. 2026 · NCT05995353

A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease

  • University of Cincinnati, Cincinnati
  • Ohio Gastroenterology group, Inc., Columbus
  • Great Lakes Gastroenterology Research, LLC, Mentor
  • in še 1
Vključevanje udeležencevFaza 4
Starost 18–70 · Vsi spoli · Posodobljeno 9. sep. 2026 · NCT06045754

A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease

  • Great Lakes Gastroenterology Research, LLC, Mentor
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 28. avg. 2026 · NCT07577843

Ultrasound-Guided Versus Standard Margin Selection in Ileocecal Resection of Terminal Ileal CD

  • Cleveland Clinic, Cleveland
Vključevanje udeležencev
Starost 18 in več · Vsi spoli · Posodobljeno 27. avg. 2026 · NCT07680283

A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease

  • Childrens Medical Center, Dayton
Vključevanje udeležencevFaza 3
Starost 2–17 · Vsi spoli · Posodobljeno 24. avg. 2026 · NCT05509777

Zymfentra (Infliximab-dyyb) REal World Cohort STudy

  • University of Cincinnati, Cincinnati
Vključevanje udeležencevOpazovalna študija
Starost 18 in več · Vsi spoli · Posodobljeno 5. avg. 2026 · NCT07237516

Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease

  • UH Cleveland Medical Center /ID# 262188, Cleveland
Vključevanje udeležencevFaza 3
Starost 2–17 · Vsi spoli · Posodobljeno 24. jun. 2026 · NCT06332534

A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)

  • University Children's Clinic, Cleveland
  • Cleveland Clinic, Cleveland
Vključevanje udeležencevFaza 3
Starost 2–17 · Vsi spoli · Posodobljeno 22. jun. 2026 · NCT06405087

Clinical, Imaging, and Endoscopic Outcomes of Children Newly Diagnosed With Crohn's Disease

  • Cincinnati Children's Hospital Medical Center, Cincinnati
  • UH/Rainbow Babies and Children's Hospital, Cleveland
  • Nationwide Children's Hospital, Columbus
Vključevanje udeležencevFaza 4
Starost 6–17 · Vsi spoli · Posodobljeno 27. maj 2026 · NCT05781152

A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)

  • University Hospitals Cleveland Medical Center - 11100 Euclid Ave, Cleveland
Vključevanje udeležencevFaza 3
Starost 2 in več · Vsi spoli · Posodobljeno 7. maj 2026 · NCT05442567

Precise Infliximab Exposure and Pharmacodynamic Control

  • Cincinnati Children's Hospital, Cincinnati
  • Cleveland Clinic Children's Hospital, Cleveland
  • Nationwide Children's Hospital, Columbus
Vključevanje udeležencevFaza 2/3
Starost 6–22 · Vsi spoli · Posodobljeno 5. maj 2026 · NCT05660746

A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)

  • University Hospitals Cleveland Medical Center, Cleveland
Vključevanje udeležencevFaza 3
Starost 2–17 · Vsi spoli · Posodobljeno 5. maj 2026 · NCT04779320

Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease

  • OSU Inflammatory Bowel Disease Center, Hilliard
Vključevanje udeležencevFaza 2
Starost 18–75 · Vsi spoli · Posodobljeno 27. apr. 2026 · NCT06456593

A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease

  • Mirador Therapeutics Selected Site, Cincinnati
  • Mirador Therapeutics Selected Site, Liberty Township
Vključevanje udeležencevFaza 2
Starost 18–80 · Vsi spoli · Posodobljeno 12. mar. 2026 · NCT07113522

Treatment of Moderate to Severe Refractory Crohn's Disease

  • Cleveland Clinic, Cleveland
Vključevanje udeležencevFaza 1/2
Starost 18–65 · Vsi spoli · Posodobljeno 10. dec. 2025 · NCT06721962

Evaluation of the SMART IBD App in Pediatric IBD

  • Cincinnati Children's Hospital Medical Center, Cincinnati
Vključevanje udeležencev
Starost 13–17 · Vsi spoli · Posodobljeno 21. nov. 2025 · NCT07195123

Development of a Novel Endoscopic Index and Patient-reported Outcome Measure for Clinical Trials in Participants With Permanent Ileostomy

  • Cleveland Clinic Foundation, Cleveland
Vključevanje udeležencevOpazovalna študija
Starost 18 in več · Vsi spoli · Posodobljeno 12. nov. 2025 · NCT06670638

Vir: ClinicalTrials.gov, podatki pridobljeni 5. okt. 2026. Vsaka študija ima svoje pogoje vključitve; ekipa študije odloči, kdo lahko sodeluje.